Mycophenolate

Patients with systemic lupus erythematosus who are vaccinated for COVID-19 demonstrate reduced antibody levels compared with vaccinated controls, according to data published in Arthritis Care & Research.

PHILADELPHIA — Withholding mycophenolate mofetil for at least 10 days following two doses of the COVID-19 vaccine significantly increased antibody response without greatly increasing the rate for flares, according to data presented here.

PHILADELPHIA — Patients with non-renal systemic lupus erythematosus who receive belimumab demonstrate a lower risk for severe infection vs. those treated with oral immunosuppressants, according to data presented at ACR Convergence 2022.

Concomitant medication burden is associated with antifibrotic medication intolerance among patients with idiopathic pulmonary fibrosis, according to research published in Annals of the American Thoracic Society.

Patients receiving mycophenolate mofetil combination therapies saw increased seroconversion after a third dose of SARS-CoV-2 vaccine, while patients on anti-CD20 and S1P modulators saw little impact from a third dose, researchers noted.

Uncovering a viable biomarker in a historically challenging disease like lupus nephritis is tantamount to striking gold if it can be used for one important purpose: Predicting treatment response.

The FDA has granted a prior approval supplement to Zydus Lifesciences Limited allowing the company to market its generic mycophenolate mofetil injection USP, 500 mg vial, following a transfer to a new manufacturing site.

Worse COVID-19 outcomes in patients with systemic lupus erythematosus are driven by comorbidities, demographics and untreated or active disease, according to data published in the Annals of the Rheumatic Diseases.

Further research is needed to ‘deconvolute’ the risk of poor COVID-19 vaccine response in patients treated with immunomodulatory drugs, according to a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.

Data presented at ACR Convergence revealed that breakthrough SARS-CoV-2 infections among patients with rheumatic diseases were more common in those who were treated with CD20 inhibitors or mycophenolate.